Sarilumab
- PDF / 168,898 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 67 Downloads / 137 Views
1 S
Thrombocytopenia during an off-label use: case report In a retrospective study of 15 patients with severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) infection, who received sarilumab from 26 March 2020 to 3 April 2020 at hospital of Italy, a patient [age and sex not stated] was described, who developed grade 2 thrombocytopenia, while receiving off-label treatment with SC sarilumab 400mg injection for SARS-COV-2 infection [time to reaction onset and outcome not stated]. Montesarchio V, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution 803519343 in Italy. Journal for ImmunoTherapy of Cancer 8: 11 Aug 2020. Available from: URL: http://doi.org/10.1136/jitc-2020-001089
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
